Fig. 4: SC1 elicits an anti-inflammatory effect by promoting the phosphorylation and extracellular release of ANX A1.
From: Annexin A1 accounts for an anti-inflammatory binding target of sesamin metabolites
a, b U937 cells treated with or without PMA and LPS were incubated with the indicated amount of SC1 for 12 h (a), and the cell lysates were analysed using western blotting with antibody against ANX A1 or phosphorylated (Ser27) ANX A1. MAPK inhibitor PD98059 was treated 1 h prior to LPS treatment (b). c, d Extracellular release of ANX A1 from U937 cells was detected using the ELISA assay as mentioned above. PD98059 was treated 1 h prior to LPS treatment (d). e U937 cells were treated with control IgG or anti-ANX A1 antibody 1 h before LPS treatment in the presence or absence of 10 μmol L−1 SC1. The TNFα production in cell culture media was analysed using ELISA. All data represent the mean ± SD (n = 3). *p < 0.05, **p < 0.01 using unpaired Student’s t test.
